Sign in
Taking people in South KoreaNo phase

Follows adults with chronic myeloid leukemia taking asciminib in Korea

Observes safety and effectiveness of asciminib in Korean adults with chronic myeloid leukemia.

Key facts

Who runs it
Novartis Pharmaceuticals
Where
Anyang-si, Bucheon-si, Gyeonggi-do, Incheon, Jeollanam, Pusan, Seoul, Suwon, Taegu, Uijeongbu-si, and Wŏnju, South KoreaSee the 11 sites
Trial code
Registry title
Asciminib RMP Study
Status
Recruiting
People taking part
600 people, planned
Started
19 Jul 2023
Expected to end
7 Jun 2030
Type of study
Observational
Treatments tested
  • Asciminib
Record updated
20 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with Ph+ chronic-phase chronic myeloid leukemia who are getting or about to get Scemblix (asciminib) under its approved label in Korea.

Age
18 to 100 years
Sex
All sexes can join.
Disease stage
Ph+ chronic-phase chronic myeloid leukemia (Ph+ CP-CML).
Earlier treatment
Must be receiving or about to receive Scemblix according to the locally approved label.
Biomarker or test result
Ph+ (Philadelphia chromosome positive) leukemia.

Main reasons for not taking part

  • Has a contraindication listed in the approved Scemblix label
  • Is receiving or will receive any investigational medicine during the observation period
  • Is not willing to give written informed consent

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Adult patients diagnosed with Ph+ CP-CML and currently receiving or going to receive Scemblix® treatment according to locally approval label
  • Patients who are willing to provide written informed consent prior to study enrollment

Who cannot take part

  • Patients with contraindication according to locally approved label of Scemblix®
  • Patients who receive or are going to receive any investigational medicine during the observation period

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 100 years old?

Where in South Korea

  • Anyang-si, Gyeonggi-doHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Bucheon-si, Gyeonggi-doHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Gyeonggi-do, KoreaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • IncheonHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • JeollanamHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • PusanHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Seoul, KoreaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Suwon, Gyeonggi-doHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • TaeguHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Uijeongbu-si, Gyeonggi-doHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Wŏnju, Gangwon-doHospital not named in the registryContact: Novartis PharmaceuticalsTaking people

About the trial

What the trial wants to find out

This study is a prospective, open-label, multi-center, non-comparative, observational study to assess safety and effectiveness of Asciminib in the real-world clinical setting in Korean Chronic myeloid leukemia (CML) patients.

The group in the trial

  • Asciminib

    Patients prescribed with Asciminib at physicians' discretion as per locally approved label under usual clinical practice

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Post Approval Surveillance of Scemblix® (Asciminib) in Patients With Chronic Myeloid Leukemia (CML) in Korea
Plain-language title
Follows adults with chronic myeloid leukemia taking asciminib in KoreaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT05943522, who can take part
Record updated
20 April 2026